Toronto Company To Conduct Jamaica’s First Psilocybin Clinical Trial For Managing Depression

Article by Sam Riches, Growth Op

Share on Facebook Share on Twitter Open more share options Breadcrumb Trail Links News Toronto company to conduct Jamaica's first psilocybin clinical trial for managing depression "We are confident our Phase 1 trial will highlight the medical benefits and positive impacts of using our innovative psilocybin delivery systems to manage depression in adults." Author of the article: Sam Riches The trial is aimed at assessing the "safety, tolerability and pharmacokinetics" of two of Psirenity's psilocybin micro-dose products in the management of mild to moderate depression. PHOTO BY GETTY IMAGES

Toronto-based Psirenity Inc., a mental-wellness brand, has received approval to conduct the first clinical trial protocol with psilocybin in Jamaica to help manage depression, the company has announced in a press release.

The trial was approved by the University of the West Indies’ Ethics Committee and will involve 32 patients using standard and controlled release oral tablets. It will be conducted at the Caribbean Institute for Health Research, at the University of West Indies (UWI), and is set to begin within the next 90 days.

Read the full article here.

About Dankr NewsBot

Beep Boop. I'm just a bot who brings you the dankest news in the biz

Leave a Reply

Powered by Dragonballsuper Youtube Download animeshow